Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Q2 2019 Earnings Conference Call - Final Transcript

Aug 08, 2019 • 04:30 pm ET


Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Q2 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good afternoon, ladies and gentlemen, and welcome to the Dicerna Pharmaceuticals Second Quarter 2019 Earnings Conference Call. [Operator Instructions]

I will now turn the call over to your host, Lauren Stival representing Dicerna Pharmaceuticals. Please go ahead.

Lauren Stival

Thank you, Operator. Good afternoon everyone, and thank you for joining us to review Dicerna's second quarter 2019 financial results and operational highlights. For anyone who has not had a chance to review our results, we issued a press release after the close of trading today, which is available under the Investors & Media tab at our website dicerna.com. You may also listen to this conference call via webcast on our website, which will be archived for 30 days beginning approximately two hours after this call has been completed.

Speaking on today's call will be our President and CEO, Doug Fambrough, who will discuss pipeline progress and key milestones for 2019 and provide an update on clinical and preclinical development activities. Then our CFO, Jack Green will review our second quarter financial results. Following our remarks, we will open the call up for your questions.

I'd like to remind listeners that management will be making forward-looking statements on this call today, including for example expected timelines and plans for development, clinical trial and regulatory milestones involving DCR-PHXC, DCR-HBVS, DCR-A1AT and other pipeline programs; expectations related to our collaboration with Eli Lilly, Alexion and Boehringer Ingelheim; expectations for discussions and possible opportunities with potential partners, collaborators and guidance regarding cash usage. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our Risk Factors section of Dicerna's latest Forms 10-Q and 10-K filed with the SEC. We may elect to update these forward-looking statements at some point in the future. We will specifically disclaim any obligation to do so, if our views change.

Now, I'd like to turn the call over to Doug Fambrough, Dicerna's President and CEO.

Douglas M. Fambrough

Thank you, Lauren. Good afternoon and thank you for joining us. With me are Jack Green, our Chief Financial Officer; and Ralf Rosskamp, our Chief Medical Officer. In the second quarter and the period leading up to this call, we continue to grow from both the corporate and a clinical progress perspective pursuant to our vision of building a fully integrated company, developing and commercializing innovative therapies for high unmet medical needs, while broadly capturing the value of our GalXC RNAi technology platform. We are pursuing this vision with a clear and focused dual strategy.

The first aspect of the strategy is to go deep on select opportunities addressing high unmet medical need with what we believe is a high probability of clinical and commercial success. Our internal clinical pipeline reflects these choices, including two rare diseases, primary hyperoxaluria and alpha-1 antitrypsin deficiency-associated liver disease where we plan to drive development and commercialization either wholly or largely on our own and one prevalent disease, chronic hepatitis B virus infection, where we are seeking a